PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.03
Negative OCF/share while Biotechnology median is -0.36. Seth Klarman would examine if a turnaround is realistic.
-0.03
Negative FCF/share while Biotechnology median is -0.42. Seth Klarman would question if the business is too capex-heavy.
No Data
No Data available this quarter, please select a different quarter.
1.93
Ratio above 1.5x Biotechnology median of 0.84. Joel Greenblatt would see if robust OCF is a recurring trait.
No Data
No Data available this quarter, please select a different quarter.